Maternal asthma affects up to 17% of pregnancies and is associated with adverse infant, childhood, and adult respiratory outcomes, including increased risks of neonatal respiratory distress syndrome, childhood wheeze and asthma. In addition to genetics, these poor outcomes are likely due to the mediating influence of maternal asthma on the in-utero environment, altering fetal lung and immune development and predisposing the offspring to later lung disease. Maternal asthma may impair glucocorticoid signalling in the fetus, a process critical for lung maturation, and increase fetal exposure to proinflammatory cytokines. Therefore, interventions to control maternal asthma, increase glucocorticoid signalling in the fetal lung, or Vitamin A, C, and D supplementation to improve alveologenesis and surfactant production may be beneficial for later lung function. This review highlights potential mechanisms underlying maternal asthma and offspring respiratory morbidities and describes how pregnancy interventions can promote optimal fetal lung development in babies of asthmatic mothers.

孕产妇哮喘影响高达 17% 的妊娠，并与婴儿、儿童和成人的不良呼吸结局相关，包括新生儿呼吸窘迫综合征、儿童喘息和哮喘的风险增加。除了遗传因素外，这些不良结果可能是由于母体哮喘对子宫内环境的中介影响，改变了胎儿的肺部和免疫发育，并使后代容易患上后来的肺部疾病。母亲哮喘可能会损害胎儿的糖皮质激素信号传导（这是肺成熟的关键过程），并增加胎儿接触促炎细胞因子的机会。因此，控制孕产妇哮喘、增加胎儿肺部糖皮质激素信号传导或补充维生素 A、C 和 D 以改善肺泡生成和表面活性剂产生的干预措施可能有益于以后的肺功能。这篇综述强调了孕产妇哮喘和后代呼吸道疾病的潜在机制，并描述了妊娠干预如何促进哮喘母亲的婴儿的最佳胎儿肺部发育。